Category: LUNG CANCER MARKER | Code: A3102
EGFR Mutation Express(4 Exons)
The EGFR mutation test is useful for determining the suitability of tyrosine kinase inhibitor (TKI) therapy in patients with non-small cell lung cancer (NSCLC). EGFR mutations are present in 38-43% of lung adenocarcinomas, and determine response to drugs such as erlotinib, afatinib, and gefitinib. This assay includes mutations at exon points 18-21, including the T790M mutation that can predict resistance to TKI therapy.
|Test Schedule||Estimated Test Result||Container||Substance||Stability|
|Monday - Friday||2 days||-||FFPE Block, Rinse||Room temperature|
The block must contain tumor cells
High Resolution Melting (HRM) PCR dan Restriction Fragment Length Polymorphism (RFLP)